给读者的信息由: Liz Highleyman撰写

StephenW

A Message To Our Readers

    Print    Email   

Details
    Category: HIV Treatment   
    Published on Friday, 29 December 2017 00:00
    Written by Liz Highleyman

alt

As of the new year, HIVandHepatitis.com will be transferred to Smart + Strong, the publisher of POZ, Hep, Real Health, and the new Cancer Health magazines and websites. HIVandHepatitis.com will remain online as an archive for the near future but will not publish new content. HIVandHepatitis.com editor Liz Highleyman is now editor-in-chief of Cancer Health.

The HIV and viral hepatitis fields have undergone a remarkable evolution since Ronald Baker founded HIVandHepatitis.com in the late 1990s. Combination antiretroviral therapy had started to reduce mortality and many people with HIV began to regain their health. But the new drug "cocktails" were often hard to take, caused difficult side effects, and did not work for many people with long-term infection and extensive treatment experience. Treatment for hepatitis C typically involved a year-long course of interferon-based therapy which also came with challenging side effects and only cured the disease about half the time.

Today, most people living with HIV can be effectively treated with a single, well-tolerated daily pill, and those who start treatment promptly have a life expectancy matching that of HIV-negative people -- and a daily pill can now prevent HIV infection in the first place. Almost everyone with hepatitis C -- including formerly "hard to treat" people such as those with HIV/HCV coinfection -- can be cured with 2 or 3 months of well-tolerated direct-acting antivirals.

But the availability of effective new therapies does not mean access. Many people living with HIV and viral hepatitis -- both in the U.S. and worldwide -- have not yet been diagnosed or are not receiving treatment for reasons including ongoing stigma, criminalization, and the high cost of new drugs.

Cancer, too, appears to be on the brink of a breakthrough. New immunotherapies -- some of them based on advances in immunology pioneered by HIV researchers -- are starting to offer some people with cancer a new lease on life. But they do not yet work for all patients or all types of cancer, and their high cost will likely require new models of health care financing.

You can turn to POZ and Hep for the latest HIV and hepatitis news and conference coverage. Liz will continue to provide conference coverage for NAM's aidsmap and infohep, as well as San Francisco HIV news for the Bay Area Reporter. The @HIVandHepatitis Twitter account will become @HealthEdOnline, touching on a broader range of health topics.

Thank you for your interest in HIVandHepatitis.com over the years. Thanks also to all our contributors, especially our content collaborators at NAM.
Best Wishes for a Happy and Healthy New Year!


-Liz Highleyman

Editor-in-chief, HIVandHepatitis.com

StephenW

给读者的信息由Liz Highleyman撰写


给读者的信息

    打印电子邮件

细节
    类别：艾滋病毒治疗
    2017年12月29日星期五00:00发布
    由Liz Highleyman撰写

ALT

截至新的一年，艾滋病和肝炎网站将被转移到智能+强，POZ，Hep，Real Health的出版商，以及新的癌症健康杂志和网站。 HIV和HEPatitis.com将在不久的将来保持在线状态，但不会公布新的内容。 HIV andHepatitis.com编辑Liz Highleyman现在是Cancer Health的主编。

自20世纪90年代后期Ronald Baker创立HIV和HEPatitis.com以来，HIV和病毒性肝炎领域发生了显着的变化。联合抗逆转录病毒疗法已经开始降低死亡率，许多艾滋病毒感染者开始恢复健康。但是新药“鸡尾酒”往往难以服用，造成了不良的副作用，而且对于长期感染和广泛治疗经验的许多人来说，并不适用。丙型肝炎的治疗通常涉及长达一年的基于干扰素治疗的疗程，其也具有具有挑战性的副作用，并且仅在大约一半的时间内治愈了该疾病。

今天，大多数感染艾滋病毒的人可以用一种耐受性良好的日常避孕药来有效治疗，那些即时开始治疗的人的预期寿命与艾滋病毒阴性人的预期寿命相匹配，而现在每天服用避孕药可以预防艾滋病毒感染第一个地方。几乎每个丙型肝炎患者 - 包括以前“难以治疗”的人群，如艾滋病毒/丙型肝炎合并感染者 - 都可以用2或3个月的耐受良好的直接抗病毒药物治愈。

但有效的新疗法的可用性并不意味着访问。许多感染艾滋病病毒和病毒性肝炎的人 - 无论是在美国还是在全世界 - 还没有被诊断，或者因为包括持续的耻辱，定罪以及新药的高成本等原因而没有得到治疗。

癌症也似乎正处于突破的边缘。新的免疫疗法 - 其中一些基于艾滋病研究人员开创的免疫学进展 - 正在开始为一些癌症患者提供新的生命契约。但是它们还不适用于所有患者或所有类型的癌症，其高成本可能需要新的医疗融资模式。

你可以求助于POZ和Hep来获得最新的HIV和肝炎新闻和会议报道。 Liz将继续为NAM的艾滋病图和信息提供会议报道，以及为“海湾地区记者”提供旧金山艾滋病新闻。 @HIVandHepatitis Twitter帐户将成为@HealthEdOnline，涉及更广泛的健康主题。

感谢您多年来对HIVandHepatitis.com的兴趣。也感谢所有的贡献者，特别是我们在NAM的内容合作者。
祝大家新年快乐，健康！


-Liz Highleyman

主编，HIV andHepatitis.com

StephenW

Top 10 HIV and Hepatitis Stories of 2017

9. Progress on Hepatitis B

In contrast with hepatitis C, hepatitis B remains difficult to cure. Nucleoside/nucleotide antivirals like tenofovir (Viread or Vemlidy) can suppress HBV replication over the long term, but they usually do not lead to a cure, as indicated by loss of hepatitis B surface antigen (HBsAg). Researchers are exploring several approaches that target different steps of the hepatitis B virus (HBV) lifecycle, including the immune-modulating drug inarigivir (SB 9200), the nucleic acid polymer REP 2139, the RNA interference therapy ARB-1467, and the capsid assembly inhibitor JNJ-56136379.
10. Fatty Liver Disease a Growing Challenge

Progress has been slow in finding treatments for non-alcoholic fatty liver disease (NALFD) and its more severe form, non-alcoholic steatosis (NASH). As an effective vaccine reduces new hepatitis B infections, contemporary treatments easily cure hepatitis C, and the population grows more obese, fatty liver disease has become a leading cause of liver disease worldwide. There are currently no approved therapies, but researchers reported this year that theacetyl-CoA carboxylase inhibitor GS-0976 reduced liver fat accumulation and fibrosis in people with NASH in a Phase 2 study. In the meantime, as this and other candidates make their way through the development pipeline, a healthy diet and exercise have been shown to improve fatty liver disease.



12/29/17

StephenW

2017年10大HIV和肝炎故事

9.乙型肝炎的进展

与丙型肝炎相反，乙型肝炎仍然难以治愈。像替诺福韦（Viread或Vemlidy）这样的核苷/核苷酸抗病毒药物可以长期抑制HBV复制，但是通常不会导致治愈，正如乙肝表面抗原（HBsAg）的缺失所表明的。研究人员正在探索几种针对乙肝病毒（HBV）生命周期不同步骤的方法，包括免疫调节药物瑞那韦（SB 9200），核酸聚合物REP 2139，RNA干扰疗法ARB-1467和衣壳组装抑制剂JNJ-56136379。
10.脂肪肝疾病越来越多的挑战

寻找治疗非酒精性脂肪肝（NALFD）及其更严重的形式，非酒精性脂肪肝（NASH）的进展缓慢。作为一种有效的疫苗可以减少新的乙型肝炎感染，现代的治疗方法很容易治愈丙型肝炎，而且人群更加肥胖，脂肪肝已经成为世界范围内肝病的主要病因。目前还没有批准的疗法，但研究人员今年报告说，在2期研究中，乙酰辅酶A羧化酶抑制剂GS-0976减少了NASH患者的肝脏脂肪堆积和纤维化。与此同时，由于这个和其他候选人通过发展渠道，健康的饮食和锻炼已被证明可以改善脂肪肝疾病。



17年12月29日

StephenW

我个人感谢Liz Highleyman和HivandHepatitis.com。 他们多年来为乙肝提供了有价值的信息，提供了光明和希望.